EFFICACY OF HALF-DOSE PHOTODYNAMIC THERAPY VERSUS HIGH-DENSITY SUBTHRESHOLD MICROPULSE LASER FOR TREATING PIGMENT EPITHELIAL DETACHMENTS IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.


Journal

Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919

Informations de publication

Date de publication:
01 04 2022
Historique:
pubmed: 6 12 2021
medline: 19 4 2022
entrez: 5 12 2021
Statut: ppublish

Résumé

Comparing the effect of half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment on retinal pigment epithelial detachments (PEDs) in chronic central serous chorioretinopathy. This study included data from the PLACE trial, a prospective randomized controlled trial comparing half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy. Main outcome measurements were changes in both the foveal PED and the highest PED within the macula at baseline compared with first and final evaluation visit. At baseline, a macular PED was detected in 76.9% of patients (123/160), and a PED within 1,500 µm from the foveal center in 37.5% of patients (60/160). In the half-dose photodynamic therapy arm (61 patients), there was a significantly larger decrease in the highest macular PED compared with the high-density subthreshold micropulse laser treatment arm (62 patients) at both first and final evaluation visits (P < 0.001 and P = 0.012, respectively). The decrease of highest foveal PED was significant at first visit (P = 0.025). Half-dose photodynamic therapy is superior to high-density subthreshold micropulse laser treatment with regard to a statistically significant reduction in the height of macular PEDs in active chronic central serous chorioretinopathy. These findings may also have implications for other diseases within the pachychoroid disease spectrum that can present with PEDs.

Identifiants

pubmed: 34864802
doi: 10.1097/IAE.0000000000003363
pii: 00006982-202204000-00015
doi:

Substances chimiques

Photosensitizing Agents 0

Banques de données

ClinicalTrials.gov
['NCT01797861']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

721-729

Références

Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82–118.
Breukink MB, Dingemans AJM, den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol 2017;11:39–46.
Mohabati D, Boon CJF, Yzer S. Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy. Clin Ophthalmol 2020;14:1165–1175.
Mohabati D, van Dijk EH, van Rijssen TJ, et al. Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. Clin Ophthalmol 2018;12:2167–2176.
Mohabati D, van Rijssen TJ, van Dijk EH, et al. Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol 2018;12:1061–1070.
Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 2019;126:576–588.
Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26–34.
Spaide RF, Ledesma-Gil G, Gemmy Cheung CM. Intervortex venous anastomosis in pachychoroid-related disorders. Retina 2020;41:997–1004.
Yang L, Jonas JB, Wei W. Optical coherence tomography–assisted enhanced depth imaging of central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2013;54:4659–4665.
Mitarai K, Gomi F, Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006;244:1415–1420.
Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 2013;33:1735–1762.
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 2019;73:100770.
van Rijssen TJ, van Dijk EHC, Scholz P, et al. Reply to comment on: focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am J Ophthalmol 2020;212:187–188.
Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 2020;395:294–303.
van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol 2021;233:101–110.
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 2018;125:1547–1555.
Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117:1792–1799.
Manabe S, Shiragami C, Hirooka K, et al. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Am J Ophthalmol 2015;159:644–651.
Loo RH, Scott IU, Flynn HW Jr., et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19–24.
Breukink MB, Downes SM, Querques G, et al. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. Trials 2015;16:419.
Wood EH, Karth PA, Sanislo SR, et al. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina 2017;37:1021–1033.
Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85:845–881.
Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010;29:144–168.
Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment. Int Ophthalmol 2017;37:483–489.
Hwang S, Kang SW, Kim SJ, et al. Photodynamic therapy for symptomatic subfoveal retinal pigment epithelial detachment in central serous chorioretinopathy: outcomes and prognostic factors. Retina 2019;39:1117–1124.
Inoda S, Takahashi H, Inoue Y, et al. Half-dose photodynamic therapy for serous non-neovascular retinal pigment epithelial detachment. Clin Ophthalmol 2019;13:959–968.
Ho M, HiuLai PingF, Siu Chun Ng D, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol 2021;105:555–560.
Yu AK, Merrill KD, Truong SN, et al. The comparative histologic effects of subthreshold 532- and 810-nm diode micropulse laser on the retina. Invest Ophthalmol Vis Sci 2013;54:2216–2224.
Karacorlu M, Ersoz MG, Arf S, et al. Long-term follow-up of pachychoroid pigment epitheliopathy and lesion characteristics. Graefes Arch Clin Exp Ophthalmol 2018;256:2319–2326.
Arif F, Pryds A, Larsen M. Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy. Acta Ophthalmol 2018;96:821–827.

Auteurs

Helena M A Feenstra (HMA)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Leo C Hahn (LC)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Thomas J van Rijssen (TJ)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Roula Tsonaka (R)

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.

Myrte B Breukink (MB)

Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.

Jan E E Keunen (JEE)

Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.

Petrus J H Peters (PJH)

Department of Ophthalmology, Bergman Clinics B.V., Velp, the Netherlands.

Greet Dijkman (G)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Eric H Souied (EH)

Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil University Paris Est, Creteil, France.

Robert E MacLaren (RE)

Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Giuseppe Querques (G)

Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil University Paris Est, Creteil, France.
Department of Ophthalmology, IRCCS Ospedale San Raffaele, Vita-Salute University, Milan, Italy.

Susan M Downes (SM)

Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Sascha Fauser (S)

Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany; and.
F. Hoffmann-La Roche, Basel, Switzerland.

Carel B Hoyng (CB)

Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.

Elon H C van Dijk (EHC)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Camiel J F Boon (CJF)

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH